-
Chest Tube–Induced Right Ventricular Failure After Cardiac Surgery JAMA Cardiol. (IF 14.8) Pub Date : 2025-05-07 Stefan R. van Dinter, Wilson W. L. Li, Nabil Saouti
This case report discusses a diagnosis of right ventricular heart failure secondary to chest tube placement during resternotomy in a male patient aged 73 years.
-
Epidemiological and Translational Study of Calprotectin and Atherosclerotic Cardiovascular Disease JAMA Cardiol. (IF 14.8) Pub Date : 2025-05-07 Yu Zuo, Somanathapura K. NaveenKumar, Sherwin Navaz, Wenying Liang, Kavya Sugur, Katarina Kmetova, Colby R. Ayers, Lyndsay Kluge, Emily Chong, Amil M. Shah, Anand Rohatgi, Jarett D. Berry, Jason S. Knight, James A. de Lemos
ImportanceInnate immunity, particularly neutrophil activation, plays a crucial role in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). The potential of calprotectin, a biomarker of neutrophil activation, as a mechanistically informed biomarker for ASCVD in an ethnically diverse population requires further investigation.ObjectiveTo examine the prospective association between circulating
-
Surgical Treatment of Hypertrophic Cardiomyopathy in Ukraine During War JAMA Cardiol. (IF 14.8) Pub Date : 2025-05-07 Barry J. Maron, Ethan J. Rowin, Martin S. Maron
This essay describes a cardiac surgeon’s experience performing surgical septal myectomy for symptomatic obstructive hypertrophic cardiomyopathy during wartime in Ukraine as related during recent interviews with the authors.
-
Intracoronary Structural-Molecular Imaging for Multitargeted Characterization of High-Risk Plaque JAMA Cardiol. (IF 14.8) Pub Date : 2025-05-07 Sunwon Kim, Hyeong Soo Nam, Dong Oh Kang, Jeongmoo Han, Hyokee Kim, Joon Woo Song, Eun Jin Park, Ryeong Hyun Kim, Hyun Jung Kim, Jin Hyuk Kim, Sunki Lee, Young Su Kim, Pyoungjae Park, Man-Jong Baik, Hongki Yoo, Jin Won Kim
ImportanceFluorescence lifetime imaging (FLIm) is a molecular imaging technique used to visualize the biochemical composition of atherosclerosis. Novel dual-modal imaging using optical coherence tomography (OCT)-FLIm has the potential to provide both microstructural and biocompositional information on coronary plaques; however, it needs validation for clinical application.ObjectiveTo investigate the
-
Effect of Alirocumab in Atherosclerotic Plaques-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-30 Flavio Giuseppe Biccirè,Lorenz Räber
-
Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-30 Leonoor F. J. M. Wijdeveld, Ezimamaka Ajufo, Saketh P. Challa, Joel T. Rämö, Xin Wang, Shinwan Kany, Jennifer L. Halford, Lu-Chen Weng, Seung Hoan Choi, Krishna G. Aragam, J. Peter van Tintelen, Bianca J. J. M. Brundel, Sean J. Jurgens, Patrick T. Ellinor
ImportancePatients with atrial fibrillation (AF), a common morbid arrhythmia, are more likely to carry rare genetic variants associated with inherited cardiomyopathies. Prior studies on rare pathogenic variants in AF relied on small, hospital referral populations, and knowledge on clinical outcomes remains limited.ObjectiveTo evaluate the prevalence and prognostic implications of cardiomyopathy-associated
-
Effect of Alirocumab in Atherosclerotic Plaques. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-30 Kyriakos Dimitriadis,Nikolaos Pyrpyris,Konstantinos Tsioufis
-
OCT vs Angiography for Guidance of Percutaneous Coronary Intervention of Calcified Lesions JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-30 Nicolas Amabile, Gregoire Rangé, Quentin Landolff, Erwan Bressollette, Nicolas Meneveau, Benoit Lattuca, Sebastien Levesque, Ziad Boueri, Julien Adjedj, Frederic Casassus, Ayoub Belfekih, Aurelie Veugeois, Géraud Souteyrand, Benjamin Honton
ImportanceThe use of intravascular imaging for calcified plaque characterization and preparation has been advocated over conventional methods to improve percutaneous coronary intervention (PCI) outcomes, but this approach has never been evaluated.ObjectiveTo determine if optical coherence tomography (OCT) is superior to angiography for calcified lesions PCI guidance.Design, Setting, and ParticipantsThe
-
OCT and Calcium-You Cannot Treat What You Cannot See. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-30 Marc-André d'Entremont,Sanjit S Jolly
-
AI-Assisted Point-of-Care Ultrasound Networks—Considerations for Rural Health Care Delivery JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-30 Amanda Chang, Jordan B. Strom, Kan Liu
This Viewpoint explores how artificial intelligence–assisted point-of-care ultrasound could be used to create coordinated networks of care to improve health care access and delivery in rural communities.
-
Financial Insecurity and Cardiometabolic Health-A Matter of Survival. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-23 Megan McLaughlin,Michelle A Albert
-
Cumulative Life’s Essential 8 Scores and Cardiovascular Disease Risk JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-23 James Walker, Daniel Won, James Guo, Jamal S. Rana, Norrina B. Allen, Hongyan Ning, Donald M. Lloyd-Jones
ImportanceMost literature on the association between cardiovascular health (CVH) and incident cardiovascular disease (CVD) and mortality has relied on single midlife measurements. Understanding how cumulative CVH over time influences later-life CVD and mortality may aid early prevention.ObjectiveTo determine whether cumulative CVH, as measured by the American Heart Association Life’s Essential 8 (LE8)
-
Cuffless Blood Pressure Measurement Devices—International Perspectives on Accuracy and Clinical Use JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-23 Eugene Yang, Aletta E. Schutte, George Stergiou, Fernando Stuardo Wyss, Yvonne Commodore-Mensah, Augustine Odili, Ian Kronish, Hae-Young Lee, Daichi Shimbo
ImportanceHypertension is a primary modifiable risk factor for cardiovascular death and disability. Accurate blood pressure (BP) measurement is essential for the diagnosis and treatment of hypertension. Conventional BP measurement with cuff devices is recommended but difficult for patients to perform due to inconvenience, discomfort, and challenges with appropriate cuff sizing and measurement protocols
-
Emergency Department–Based Education and mHealth Empowerment Intervention for Hypertension JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-23 Heather Prendergast, Spyros Kitsiou, Renee Petzel Gimbar, Sally Freels, Anissa Sanders, Martha Daviglus, Pavitra Kotini-Shah, Barry Carter, Marina Del Rios, Sara Heinert, Shaveta Khosla
ImportanceHypertension is a leading risk factor for cardiovascular diseases and is often undiagnosed. Emergency department (ED) visits serve as critical access points within health care and present a unique opportunity for hypertension screening and intervention.ObjectiveTo evaluate the effectiveness of an Education and mHealth Empowerment (E2) intervention compared with usual care in reducing systolic
-
Temporary Mechanical Cardiac Support Outcomes and Cardiogenic Shock-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-16 Jacob Eifer Møller,Nanna Louise Junker Udesen,Christian Hassager
-
Temporary Mechanical Cardiac Support Outcomes and Cardiogenic Shock. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-16 Federico Pappalardo,Nicoletta D'Ettore,Andrea Montisci
-
Artificial Intelligence–Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-16 Lovedeep S. Dhingra, Arya Aminorroaya, Aline F. Pedroso, Akshay Khunte, Veer Sangha, Daniel McIntyre, Clara K. Chow, Folkert W. Asselbergs, Luisa C. C. Brant, Sandhi M. Barreto, Antonio Luiz P. Ribeiro, Harlan M. Krumholz, Evangelos K. Oikonomou, Rohan Khera
ImportanceDespite the availability of disease-modifying therapies, scalable strategies for heart failure (HF) risk stratification remain elusive. Portable devices capable of recording single-lead electrocardiograms (ECGs) may enable large-scale community-based risk assessment.ObjectiveTo evaluate whether an artificial intelligence (AI) algorithm can predict HF risk from noisy single-lead ECGs.Design
-
Automated Deep Learning Phenotyping of Tricuspid Regurgitation in Echocardiography JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-16 Amey Vrudhula, Milos Vukadinovic, Christiane Haeffele, Alan C. Kwan, Daniel Berman, David Liang, Robert Siegel, Susan Cheng, David Ouyang
ImportanceAccurate assessment of tricuspid regurgitation (TR) is necessary for identification and risk stratification.ObjectiveTo design a deep learning computer vision workflow for identifying color Doppler echocardiogram videos and characterizing TR severity.Design, Setting, and ParticipantsAn automated deep learning workflow was developed using 47 312 studies (2 079 898 videos) from Cedars-Sinai
-
Periconceptional Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-16 Sadiya S. Khan, William A. Grobman, Dhruv S. Kazi
This Viewpoint describes the need for more studies on the best timing for dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
-
Progressive Kidney Dysfunction After Left Atrial Appendage Closure. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-09 Shuaishuai Yuan,Chao Tao,Peijun Li
-
Self-Administered Etripamil and Emergency Department Visits in Supraventricular Tachycardia JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-09 Sean D. Pokorney, A. John Camm, Paul Dorian, James E. Ip, Bruce S. Stambler, David B. Bharucha, Jonathan P. Piccini
This secondary analysis of a randomized clinical trial describes the use of emergency care after self-administration of etripamil by patients experiencing paroxysmal supraventricular tachycardia episodes at home.
-
Accountable Care Organization Participation and Cardiovascular Care Quality JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-04 Erica S. Spatz, D. August Oddleifson, Jehanzeb Kayani, Kensey L. Gosch, Philip G. Jones, Rushabh H. Doshi, Thomas M. Maddox, Nihar R. Desai
ImportanceThe Medicare Shared Savings Program (MSSP) was introduced in 2012 to improve care quality and lower costs to Medicare. Under this program, accountable care organizations (ACOs) assumed responsibility for costs and care quality for a group of Medicare beneficiaries.ObjectiveTo compare changes in quality measures for patients at outpatient cardiology practices before and after their participation
-
Hypertensive Disorders of Pregnancy and Long-Term Risk of Dilated Cardiomyopathy JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-04 Upasana Tayal, Constantinos Kallis, Georgie M. Massen, Nora Rossberg, Emily L. Graul, Jennifer K. Quint
ImportanceThe impact of hypertensive disorders of pregnancy on developing dilated cardiomyopathy is unknown.ObjectiveTo determine whether hypertensive disorders of pregnancy are associated with long-term risk of dilated cardiomyopathy.Design, Setting, and ParticipantsThis population-based cohort study performed in England used the following linked electronic health records databases: Clinical Practice
-
Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-02 Priya M Freaney,Xiaoning Huang,Lucia C Petito,William A Grobman,Janet Catov,Alisse Hauspurg,C Noel Bairey Merz,Natalie Bello,Jin Kyung Kim,Abbi Lane,David M Haas,Lisa D Levine,Rebecca B McNeil,Eliza Miller,George Saade,Lauren Theilen,Lynn M Yee,Jasmina Varagic,Brian Mercer,Uma Reddy,Donald M Lloyd-Jones,Philip Greenland,Sadiya S Khan,
-
Rural America-Expanding the Lens of Health Disparities: Endorsing the Need for Health Equity Research. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-31 Sadiya S Khan,Clyde W Yancy
-
Mining the Electronic Medical Record for Hypertension Treatment-Hope or Hype? JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-31 Sadiya S Khan
-
Cardiovascular Health Among Rural and Urban US Adults—Healthcare, Lifestyle, and Social Factors JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-31 Michael Liu, Lucas X. Marinacci, Karen E. Joynt Maddox, Rishi K. Wadhera
ImportanceImproving cardiovascular health in rural areas is a national priority in the US. However, little is known about the current state of rural cardiovascular health and the underlying drivers of any rural-urban disparities.ObjectiveTo compare rates of cardiometabolic risk factors and cardiovascular diseases between rural and urban US adults and to evaluate the extent to which health care access
-
Leveraging Preexisting Cardiovascular Data to Improve the Detection and Treatment of Hypertension JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-31 Adam N. Berman, Michael K. Hidrue, Curtis Ginder, Linnea Shirkey, Japneet Kwatra, Anna C. O’Kelly, Sean P. Murphy, Jennifer M. Searl Como, Danielle Daly, Yee-Ping Sun, William T. Curry, Marcela G. del Carmen, Ron Blankstein, John A. Dodson, David A. Morrow, Benjamin M. Scirica, Niteesh K. Choudhry, James L. Januzzi, Jason H. Wasfy
ImportanceHypertension is often underrecognized, leading to preventable morbidity and mortality. Tailored data systems combined with care augmented by trained nonphysicians have the potential to improve cardiovascular care.ObjectiveTo determine whether previously collected cardiovascular imaging data could be harnessed to improve the detection and treatment of hypertension through a system-level intervention
-
Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-30 Akshay S. Desai, Pardeep S. Jhund, Muthiah Vaduganathan, Brian L. Claggett, Jonathan W. Cunningham, Maria A. Pabon, Carolyn S. P. Lam, Michele Senni, Sanjiv Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay-Flurrie, Markus F. Scheerer, Andrea Lage, John J. V. McMurray, Scott D. Solomon
ImportanceThe mode of death in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF) remains poorly understood and may vary by EF.ObjectiveTo evaluate the mode of death according to EF and the treatment effect of finerenone on cause-specific mortality in patients with HFmrEF/HFpEF.Design, Setting, and ParticipantsThis was
-
Finerenone and Atrial Fibrillation in Heart Failure JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-29 Shingo Matsumoto, Alasdair D. Henderson, Pardeep S. Jhund, Johann Bauersachs, Ovidiu Chioncel, Brian L. Claggett, Josep Comin-Colet, Akshay S. Desai, Gerasimos Filippatos, Carolyn S. P. Lam, Bertram Pitt, Markus Florian Scheerer, James Lay-Flurrie, Flaviana Amarante, Meike Brinker, Morten Schou, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Shelley Zieroth, Muthiah Vaduganathan, Scott
ImportanceHeart failure (HF) with mildly reduced or preserved ejection fraction and atrial fibrillation (AF) are closely intertwined.ObjectiveTo examine the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with HF with mildly reduced or preserved ejection fraction according to the absence or presence of AF and the type of AF (paroxysmal vs persistent
-
Aortic Valve Intervention for Asymptomatic Aortic Stenosis. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-26 Rick A Nishimura,Patrick T O'Gara,Robert O Bonow
-
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-26 John H. Alexander, Elizabeth J. Lydon, Jonathan P. Piccini, Thomas Viethen, Jonas Oldgren, Shaun G. Goodman, Jan Steffel, Andrea M. Russo, Isabelle C. van Gelder, Keith C. Ferdinand, Renato D. Lopes, Hardi Mundl, Bela Benczur, Juan José Gómez-Doblas, Michael Glikson, Assen Goudev, Erik L. Grove, Sigrun Halvorsen, Tuomas Kiviniemi, Anne-Céline Martin, Roopinder K. Sandhu, Dragos Vinereanu, Frank W.
ImportanceIn patients with atrial fibrillation (AF), oral anticoagulants (OACs) reduce the risk of stroke.ObjectiveTo investigate if patients with less prior OAC exposure respond differently to a new OAC than patients with more OAC exposure.Design, Setting, and ParticipantsIn this prespecified exploratory subgroup analysis of the Oral Factor 11a Inhibitor Asundexian as Novel Antithrombotic–Atrial Fibrillation
-
Encouraging Pharmacist Referrals for Evidence-Based Statin Initiation JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-26 Alexander C. Fanaroff, Qian Huang, Kayla Clark, Laurie A. Norton, Wendell E. Kellum, Dwight Eichelberger, John C. Wood, Zachary Bricker, Andrea G. Dooley Wood, Greta Kemmer, Jennifer I. Smith, Srinath Adusumalli, Mary E. Putt, Kevin G. Volpp
ImportanceDespite statins’ benefit in preventing major adverse cardiovascular events, most patients with an indication for statin therapy are not appropriately treated. Clinicians’ limited time and lack of systematic efforts to address preventive care likely contribute to gaps in statin prescribing.ObjectiveTo determine the effect on statin prescribing of 2 interventions to refer appropriate patients
-
Peak Oxygen Uptake vs Ventilatory Efficiency. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-19 Jiawei Du,Jinghua Hou
-
Peak Oxygen Uptake Vs Ventilatory Efficiency-In Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-19 Matthew M Y Lee,Gregory D Lewis
-
A Man in His 30s With Ponytail Coronary Artery Anomaly. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-19 Leizhi Ku,Xiaojing Ma
-
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-19 Wenxiu Wang, Rui Li, Zimin Song, Ninghao Huang, Tao Huang, Xinwei Hua, Yi-Da Tang
ImportanceDespite substantial progress in low-density lipoprotein cholesterol (LDL-C)–lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lowering triglycerides. Multiple clinical trials of small-interfering RNA therapeutics targeting APOC3 are currently underway.ObjectiveTo investigate whether genetically predicted lower APOC3 is associated
-
Concomitant Mechanical Aspiration and Appendage Closure for Recalcitrant Left Atrial Appendage Thrombi JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-19 Maryam Saleem, Abhishek Maan, Daniel R. Musikantow, Chi Zhang, Yury Malyshev, Marc A. Miller, Srinivas R. Dukkipati, Parasuram M. Krishnamoorthy, Martin Goldman, Prakash Krishnan, Vivek Y. Reddy
ImportanceIt is well appreciated that a small yet high-risk subset of patients with atrial fibrillation (AF) develops persistent left atrial appendage (LAA) thrombus despite optimal oral anticoagulation (OAC). In patients with either a heightened risk of bleeding precluding enhanced doses of OAC to dissolve the thrombus, or thromboembolism despite optimal OAC, there are limited nonsurgical options
-
FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-12 Kuniaki Takahashi,Hisao Otsuki,Frederik M Zimmermann,Victoria Y Ding,Thomas Engstrøm,Hans Gustav Hørsted Thyregod,Branko Beleslin,Svetozar Putnik,Luke Tapp,Thomas Barker,Simon Redwood,Christopher Young,G Jan-Willem Bech,Gerard J F Hoohenkerk,Bernard De Bruyne,Nico H J Pijls,William F Fearon,
Importance Outcomes in patients with diabetes after fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) using current-generation drug-eluting stents (DES) compared with coronary artery bypass grafting (CABG) are unknown. Objectives To investigate the relative treatment effect of PCI vs CABG according to diabetes status with respect to major adverse cardiac and cerebrovascular
-
Food Insecurity and Incident Cardiovascular Disease Among Black and White US Individuals, 2000-2020 JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-12 Jenny Jia, Mercedes R. Carnethon, Mandy Wong, Cora E. Lewis, Pamela J. Schreiner, Namratha R. Kandula
ImportanceFood insecurity is associated with prevalent cardiovascular disease (CVD), but studies have been limited to cross-sectional data.ObjectivesTo study whether food insecurity is associated with incident CVD and to determine whether this association varies by sex, education, or race.Design, Setting, and ParticipantsThis prospective cohort study was conducted among US adults without preexisting
-
Exercise-Induced Dyspnea in an Older Woman With a History of Coronary Artery Disease JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-12 Soundous M’Rabet, Jean-Christophe Eicher, Charles Guenancia
An older woman with a history of coronary artery disease presents with dyspnea upon exertion. A transthoracic echocardiogram reveals severe mitral regurgitation, and an electrocardiogram reveals sinus tachycardia with left bundle branch block. What would you do next?
-
Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-12 Ambarish Pandey, Gregory D. Lewis, Barry A. Borlaug, Sanjiv J. Shah, Andrew J. Sauer, Sheldon Litwin, Kavita Sharma, Diane K. Jorkasky, Elizabeth A. Tarka, Shaharyar M. Khan, Dalane W. Kitzman
ImportanceExcess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.ObjectiveTo assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and
-
Filling the Evidence Gaps Toward a Coronary Artery Calcium-Guided Primary Prevention Strategy. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-05 Michael J Blaha
-
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-05 John W Ostrominski,Brian L Claggett,Michael Jerosch-Herold,Anna Axelsson Raja,Sharlene M Day,Mark W Russell,Kenneth Zahka,Alexandre C Pereira,Steven D Colan,Anne M Murphy,Charles Canter,Richard G Bach,Matthew T Wheeler,Joseph W Rossano,Anjali T Owens,Luisa Mestroni,Matthew R G Taylor,Amit R Patel,Ivan Wilmot,Jonathan H Soslow,Jason R Becker,Neal K Lakdawala,Henning Bundgaard,Jose D Vargas,Carolyn Y
Importance Valsartan has been shown to attenuate phenotypic progression among individuals with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Myocardial tissue characterization by cardiac magnetic resonance (CMR) imaging may enhance mechanistic insights, but whether valsartan influences these parameters remains uncertain. Objective To evaluate the treatment effects of valsartan on myocardial
-
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-05 Kirsty McDowell, Kieran F. Docherty, Ross T. Campbell, Alasdair D. Henderson, Pardeep S. Jhund, Brian L. Claggett, Akshay S. Desai, James Lay-Flurrie, Lucas Hofmeister, Andrea Scalise, Carolyn S. P. Lam, Mark C. Petrie, Morten Schou, Michele Senni, Sanjiv J. Shah, Jacob A. Udell, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J. V. McMurray
ImportancePatients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) have a spectrum of risk, and the effect of therapies may vary by risk.ObjectivesTo validate the Prognostic Models for Mortality and Morbidity in HFpEF (PREDICT-HFpEF) in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo
-
Coronary Artery Calcium Testing—Too Early, Too Late, Too Often JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-05 Alexander R. Zheutlin, Anuj K. Chokshi, John T. Wilkins, Neil J. Stone
ImportanceTraditional risk factors, enhancing factors, and risk scores help clinicians assess atherosclerotic cardiovascular disease (ASCVD) risk for primary prevention. The latest cholesterol guidelines suggest measuring coronary artery calcium (CAC) score by computed tomography (CT) in those at intermediate risk when there is uncertainty about statin initiation for primary prevention. CAC testing
-
Importance of Age and Sex in Carotid Artery Plaque Detection and Cardiovascular Disease Risk JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-05 Matthew C. Tattersall, Spencer L. Hansen, Robyn L. McClelland, Claudia E. Korcarz, Kristin M. Hansen, Wendy S. Post, Michael D. Shapiro, James H. Stein
ImportanceCarotid artery plaque (CAP) is commonly encountered in clinical practice. Presence of CAP predicts future atherosclerotic cardiovascular disease (ASCVD) events; however, CAP prevalence increases with age, and it is unknown how age and sex affect the association of CAP presence and ASCVD risk.ObjectivesTo describe CAP prevalence by age, sex, race, and ethnicity in a multiethnic population
-
Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-05 Stephen J. Greene, Javed Butler, Gregg C. Fonarow
This Viewpoint recommends simultaneous or rapid sequence initiation of combination therapy with 3 specific classes of medication for heart failure with mildly reduced ejection fraction or preserved ejection fraction.
-
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2025-02-26 Jonathan W. Cunningham, Safia Chatur, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Guillermo Llamas Esperón, Carolyn S. P. Lam, Naoki Sato, Michele Senni, Sanjiv Shah, Adriaan Voors, Faiez Zannad, Bertram Pitt, Shelley Zieroth, Meike Brinker, Katja Rohwedder, So-Young Kim, James Lay-Flurrie, Prabhakar Viswanathan, John J. V. McMurray, Scott D. Solomon
ImportanceWorsening heart failure (HF) is commonly managed in the outpatient setting with adjustments in oral diuretic therapy. The effect of the nonsteroidal mineralocorticoid receptor antagonist finerenone on outpatient worsening HF events in patients with mildly reduced or preserved ejection fraction is unknown.ObjectiveTo evaluate the effect of finerenone on outpatient worsening HF events requiring
-
New Right Atrial Image After Coronary Revascularization Surgery JAMA Cardiol. (IF 14.8) Pub Date : 2025-02-26 Clara Nuevo-Gallardo, María Reyes González-Fernández, María Yuste-Domínguez
This case report describes a saphenous vein graft simulating an intracardiac structure on echocardiography of a patient after coronary revascularization surgery.
-
Safety, Feasibility, and Diagnostic Yield of Invasive Coronary Function Testing: Netherlands Registry of Invasive Coronary Vasomotor Function Testing. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-01 Caïa Crooijmans,Tijn P J Jansen,Joan G Meeder,Janneke Woudstra,Martijn Meuwissen,Annemiek M J De Vos,Valeria Paradies,Els G M Olde Bijvank,Patty Winkler,Nicola S Vos,Karin Arkenbout,Pier Woudstra,Martin G Stoel,Tim P Van de Hoef,Stijn C H Van den Oord,Jos W M G Widdershoven,Wouter Remkes,Aysun Cetinyurek-Yavuz,Hester M Den Ruijter,N Charlotte Onland-Moret,Eric Boersma,Marcel A M Beijk,Yolande Appelman
Importance Patients with angina and no obstructive coronary artery disease frequently have coronary vasomotor dysfunction as underlying pathophysiological mechanism, comprising epicardial spasm, microvascular spasm, and/or microcirculatory dysfunction. These endotypes can be diagnosed by invasive coronary function testing which has previously shown to be safe in tertiary and expert centers. Objective
-
Donning the Hijab-A Cardiology Fellow's Journey With Advocacy and Inclusion. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-01 Najah Ali Khan
-
Sex-Specific Association of Myocardial Fibrosis With Mortality in Patients With Aortic Stenosis JAMA Cardiol. (IF 14.8) Pub Date : 2025-02-19 Soongu Kwak, Anvesha Singh, Russell J. Everett, Thomas A. Treibel, Jaehyun Lim, Sungho Won, Michelle C. Williams, Krithika Loganathan, Rong Bing, Neil Craig, Trisha Singh, Shruti Joshi, Heesun Lee, Whal Lee, Yong-Jin Kim, Calvin W. L. Chin, Miho Fukui, Tarique Al Musa, Marzia Rigolli, Lionel Tastet, Laura E. Dobson, Stephanie Wiesemann, Vanessa M. Ferreira, Gabriella Captur, Sahmin Lee, Jeanette Schulz-Menger
ImportanceMyocardial fibrosis in aortic stenosis (AS) may exhibit sex differences. However, its prognostic significance in women with AS remains unclear.ObjectiveTo investigate sex differences in myocardial fibrosis assessed by cardiovascular magnetic resonance (CMR) and evaluate its prognostic value in women and men with AS.Design, Setting, and ParticipantsPatients with severe AS who underwent CMR
-
Intensive Blood Pressure Control in Older Adults-Reply. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-01 Xiaofan Guo,Guozhe Sun,Yingxian Sun
-
Intensive Blood Pressure Control in Older Adults. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-01 Yuxian Huang,Xiangmin Tan
-
Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-01 ,Marta Gigli,Davide Stolfo,Giulia Barbati,Sharon Graw,Suet Nee Chen,Marco Merlo,Kristen Medo,Caterina Gregorio,Matteo Dal Ferro,Alessia Paldino,Maria Perotto,J Peter van Tintelen,Anneline S J M Te Riele,Annette F Baas,Arthur M Wilde,Ahmad S Amin,Arjan C Houweling,Perry Elliott,Douglas Cannie,Michelle Michels,Stephan A C Schoonvelde,Sanjay Prasad,Paz Upasana Tayal,Momina Yazdani,Deborah Morris-Rosendahl
Importance Filamin C truncating variants (FLNCtv) are a rare cause of cardiomyopathy with heterogeneous phenotypic presentations. Despite a high incidence of life-threatening ventricular arrhythmias and sudden cardiac death (SCD), reliable risk predictors to stratify carriers of FLNCtv are lacking. Objective To determine factors predictive of SCD/major ventricular arrhythmias (MVA) in carriers of FLNCtv
-
Patient Enrollment for Cardiovascular Clinical Trials in the United States. JAMA Cardiol. (IF 14.8) Pub Date : 2025-03-01 Muhammad Shahzeb Khan,Adeena Jamil,Muteia Shakoor,Stephen J Greene,Gregg C Fonarow,Deepak L Bhatt,J Michael DiMaio,Michael J Mack,Javed Butler
-
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial. JAMA Cardiol. (IF 14.8) Pub Date : 2025-02-12 Robert S Rosenson,J Antonio G López,Daniel Gaudet,Seth J Baum,Elmer Stout,Norman E Lepor,Jeong-Gun Park,Sabina A Murphy,Beat Knusel,Jingying Wang,Tomaz Wilmanski,Huei Wang,You Wu,Helina Kassahun,Marc S Sabatine,Michelle L O'Donoghue,
Importance Lipoprotein(a) (Lp[a]) is thought to be the major carrier of oxidized phospholipids (OxPL). OxPL are believed to be a potent driver of inflammation and atherosclerosis. Olpasiran, a small interfering RNA, blocks Lp(a) production by inducing degradation of apolipoprotein(a) messenger RNA. Olpasiran's effects on OxPL and systemic markers of inflammation are not well described. Objective To
-
Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis—The Time Has Come JAMA Cardiol. (IF 14.8) Pub Date : 2025-02-12 Brian R. Lindman, Eugene Braunwald, Patricia A. Pellikka
This Viewpoint advocates for prompt aortic valve replacement (rather than clinical surveillance) as the default strategy for patients with asymptomatic severe aortic stenosis.
-
The Cardiovascular Disease Divide-A Tale of 2 High-Income Nations. JAMA Cardiol. (IF 14.8) Pub Date : 2025-04-01 Sadiya S Khan